Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Zusammenfassung
Prospective 12-month follow-up of psilocybin-assisted therapy for major depressive disorder showed sustained antidepressant effects, with response rates maintained at 75% and remission rates at 58% at 12 months post-treatment.
Schlüsselwörter
psilocybindepressionlong-term follow-up12-monthMDD
Klinische Forschung